Patents by Inventor Futa Mimoto

Futa Mimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240190960
    Abstract: The present invention relates to a first antigen-binding molecule, a second antigen-binding molecule, and a combination thereof. The second antigen-binding molecule binds to an antigen/antigen-binding molecule complex containing a first antigen and the first antigen-binding molecule, and enhances the binding activity of the first antigen-binding molecule to the first antigen.
    Type: Application
    Filed: December 22, 2023
    Publication date: June 13, 2024
    Inventors: Tomoyuki IGAWA, Naoka HIRONIWA, Shogo KAMIKAWAJI, Tatsuya KIBAYASHI, Nasa SAVORY, Futa MIMOTO
  • Publication number: 20240117059
    Abstract: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug a
    Type: Application
    Filed: December 8, 2023
    Publication date: April 11, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Futa Mimoto, Taichi Kuramochi
  • Publication number: 20230257470
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 17, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • Patent number: 11718678
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 8, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • Publication number: 20230174655
    Abstract: An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of Fc?RIIa, types H and R, and having enhanced Fc?RIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of Fc?RIIa and enhancing the Fc?RIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances Fc?RIIb-binding activity, and maintains or decreases binding activities towards both allotypes of Fc?RIIa, types H and R.
    Type: Application
    Filed: June 22, 2022
    Publication date: June 8, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Futa Mimoto, Taichi Kuramochi, Tomoyuki Igawa, Hitoshi Katada, Shojiro Kadono
  • Publication number: 20230140797
    Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 4, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Hitoshi Katada, Shojiro Kadono, Futa Mimoto
  • Publication number: 20220411483
    Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
    Type: Application
    Filed: February 14, 2022
    Publication date: December 29, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
  • Publication number: 20220242934
    Abstract: The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and Fc?R, but does not bind to the antigen and the Fc?R at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and Fc?R at the same time. Thus, the present invention provides a polypeptide suitable as a drug.
    Type: Application
    Filed: September 24, 2021
    Publication date: August 4, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Naoka Hironiwa, Shojiro Kadono, Atsushi Matsuo, Taichi Kuramochi, Futa Mimoto
  • Patent number: 11267868
    Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: March 8, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
  • Patent number: 11236168
    Abstract: The present inventors have successfully found a large number of Fc variants with remarkably increased binding activity against and/or binding selectivity for mouse Fc?RII by introducing amino acid alteration(s) to the Fc region.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: February 1, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Eriko Murata, Futa Mimoto
  • Publication number: 20210324099
    Abstract: An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.
    Type: Application
    Filed: August 9, 2019
    Publication date: October 21, 2021
    Inventors: Tomoyuki IGAWA, Mika SAKURAI, Shun SHIMIZU, Yuji HORI, Naoka HIRONIWA, Nasa SAVORY, Yoshinori NARITA, Takayuki KAMIKAWA, Taro MIYAZAKI, Shojiro KADONO, Masami HASEGAWA, Kanako TATSUMI, Akira HAYASAKA, Takeaki KAWAI, Futa MIMOTO, Hiroki KAWAUCHI, Masaki KAMIMURA
  • Patent number: 11142563
    Abstract: The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and Fc?R, but does not bind to the antigen and the Fc?R at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and Fc?R at the same time. Thus, the present invention provides a polypeptide suitable as a drug.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 12, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Naoka Hironiwa, Shojiro Kadono, Atsushi Matsuo, Taichi Kuramochi, Futa Mimoto
  • Patent number: 11124576
    Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating, under a reducing condition, homo variants of plural types of polypeptides in which the alteration of amino acids that form the interface between Fc regions and/or the alteration to destabilize the stability of a heavy chain CH3 region has been introduced in the heavy chain CH3 regions so at to achieve the promotion of the dissociation of the Fc regions and/or the control of the association thereof through the use of charge repulsion.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: September 21, 2021
    Assignee: Chungai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hitoshi Katada, Futa Mimoto
  • Publication number: 20210261648
    Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).
    Type: Application
    Filed: September 22, 2020
    Publication date: August 26, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
  • Patent number: 10919953
    Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: February 16, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
  • Publication number: 20200399373
    Abstract: The present invention relates to a first antigen-binding molecule, a second antigen-binding molecule, and a combination thereof. The second antigen-binding molecule binds to an antigen/antigen-binding molecule complex containing a first antigen and the first antigen-binding molecule, and enhances the binding activity of the first antigen-binding molecule to the first antigen.
    Type: Application
    Filed: February 14, 2019
    Publication date: December 24, 2020
    Inventors: Tomoyuki IGAWA, Naoka HIRONIWA, Shogo KAMIKAWAJI, Tatsuya KIBAYASHI, Nasa SAVORY, Futa MIMOTO
  • Patent number: 10766960
    Abstract: The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 8, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Futa Mimoto, Hitoshi Katada, Hirotake Shiraiwa
  • Publication number: 20200199241
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • Publication number: 20200181257
    Abstract: Polypeptides with improved stability as compared to that of a parent polypeptide were successfully obtained by modifying at least one amino acid in a loop region of the antibody Fc region. Furthermore, by combining multiple amino acid modifications in the loop region, polypeptides with maintained or enhanced Fc?R-binding activity as well as improved thermal stability, polypeptides with decreased Fc?R-binding activity as well as improved thermal stability, and polypeptides with not only improved thermal stability and adjusted Fc?R-binding activity but also decreased aggregate content, as compared to those of a parent polypeptide, were successfully obtained.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 11, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Taichi Kuramochi, Meiri Kawazoe, Futa Mimoto, Atsuhiko Maeda, Tomoyuki Igawa
  • Patent number: 10618965
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 14, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono